Loading...

COCH ENVOY MEDICAL INC Management Changes 8-K Filing

NVY

CCH

ENVOY MEDICAL INC

(COCH)

2026 8-K

Financial Results Update

Board Appointment

Audit Firm Change

Financial Results Released

Nasdaq Compliance Confirmed

Public Offering Announcement

Executive Stock Options

Warrant Amendment

Investor Presentation Update

Stockholder Approval

Nasdaq Compliance Notice

Financial Results Update

Nasdaq Compliance Exception

Securities Purchase Agreement

FDA Approval Granted

Securities Offering

Voting Agreement Update

Listing Compliance Update

Debt Settlement Announcement

Financial Statements

Warrant Amendments

Debt-Equity Swaps

Contract Renewal

Financial Statements

Financial Results

Funding Agreement

Nasdaq Notification

Warrant Issuance

Capital Structure Change

Capital Structure Change

Q3 Financial Results

Annual Meeting Notice

Funding Agreement

Financial Results

Regulation FD Disclosure

Forward Purchase Agreement ...

Entry Into a Material Defin...

Regulation FD Disclosure

Forward Purchase Agreement

Director Resignation and Ap...

Promissory Note and Warrant...

Entry Into a Material Defin...

Restatement of Financial St...

Changes in Registrant s Cer...

Employment Agreement with CEO

Settlement of Lawsuit

Amendment to Financial Info...

Change of Control

Special Meeting Approval

Business Combination Agreement

Business Combination Agreement

Restatement of Financial St...

Amendment and Voting Results

Extension Support Agreements

Announcement of Special Mee...

Adjournment of Special Meeting

Extension of Business Combi...

External Links:

On February 5, 2026, Envoy Medical, Inc. awarded stock options to CEO Brent Lucas (200,000 shares) and Interim CFO Robert Potashnick (15,000 shares) at an exercise price of $0.53 per share, vesting over four years. This filing falls under 'Changes in management or control'.

AI Assistant

ENVOY MEDICAL INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.